What changed for Vitiligo
A plain English summary of what recently moved in the public data Voxsanity tracks for Vitiligo. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 35 to 34 (-1)
- Trials on record 305 to 299 (-6)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Vitiligo yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Vitiligo that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05750823 · results posted 20 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 49 adults who used a cream called ruxolitinib 1.5% applied twice daily to areas of genital vitiligo — a condition where patches of skin lose their colour. There was only one group, meaning everyone received the same cream; there was no comparison group receiving a dummy (placebo) treatment. Of the 49 people who started, 35 completed the trial and 14 did not finish. The trial ran for 48 weeks and tracked several things, including how noticeable participants felt their vitiligo was compared to when they started, how doc...
-
NCT06113328 · results posted 17 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06113328) tested an investigational medicine called MK-6194 in people with vitiligo — a skin condition where patches of skin lose their colour. A total of 169 participants took part in the initial double-blind phase, split into three groups: 57 received MK-6194 by injection every two weeks (Q2W), 55 received it every four weeks (Q4W), and 57 received a placebo (a dummy treatment with no active ingredient). Those who completed that phase could continue into an extension period. The trial was primarily measuring changes in t...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04953338 · results posted 2 December 2025
According to the results reported on ClinicalTrials.gov, this study looked at whether adults diagnosed with vitiligo (a skin condition that causes patches of skin to lose their colour) were more likely to be recorded as having certain mental health conditions compared to adults without vitiligo. The study included 7,224 people with vitiligo (the "cases" group) and 28,880 people without vitiligo (the "controls" group), and no participants were recorded as dropping out. The reported data shows that among the vitiligo group, 1,018 participants had a recorded depressive episode, 1,093 had recurre...
-
NCT04338581 · results posted 17 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04338581) enrolled 60 people with vitiligo — 40 received the investigational treatment AMG 714 and 20 received a placebo (an inactive comparison treatment). Of those, 34 in the AMG 714 group and 16 in the placebo group completed the study. The trial was measuring changes in the amount of facial skin affected by vitiligo, using a scoring tool called the Facial Vitiligo Area Scoring Index (F-VASI), which rates the extent and degree of colour loss on the face. The main question the trial set out to answer was what proportion...
-
NCT06097494 · results posted 17 March 2025
According to the results reported on ClinicalTrials.gov, this study looked at records from 39,374 people in total — 7,890 people with vitiligo (a skin condition where patches of skin lose their colour) and 31,484 people without vitiligo who served as a comparison group. The study was measuring whether people with vitiligo were more or less likely to have recorded diagnoses of depression or anxiety, and whether there were differences in how often both groups visited their GP, were referred to a skin specialist (dermatologist), or were referred for mental health support. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05247489 · results posted 20 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05247489) enrolled 55 people with vitiligo — 20 in a group using ruxolitinib 1.5% cream twice daily on its own, and 35 in a group using the same cream combined with a type of light therapy called narrowband ultraviolet B (NB-UVB). The trial mainly looked at how much the overall extent of vitiligo (measured using a scoring system called T-VASI, where a lower score means less affected skin) changed over 48 weeks. By the end of the study, 6 people in the cream-only group and 26 in the combination group had completed the trial...
-
NCT04969419 · results posted 14 January 2025
According to the results reported on ClinicalTrials.gov, this study looked at whether adults with vitiligo (a skin condition that causes patches of skin to lose their colour) were more or less likely to develop new skin cancers compared to people without vitiligo. The study tracked 15,156 people with vitiligo (called "cases") and 60,615 people without vitiligo (called "controls" — a comparison group matched to the cases). The skin cancers being counted included melanoma, squamous cell carcinoma, and basal cell carcinoma. The reported data shows that, overall, 133 people in the vitiligo group...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04374435 · results posted 5 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 17 people in total across three groups. Seven participants received a skin cell transplant procedure (known as MKTP) using a surgical blade, seven received the same type of transplant using a negative pressure instrument (a device that uses suction), and three received a different technique called suction blister grafting without cell separation. All 17 participants completed the trial. The trial was measuring changes in the affected skin area in people with vitiligo — a condition where patches of skin lose their colo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04811131 · results posted 12 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04811131) enrolled 114 adults across four groups to test combinations of an investigational product (referred to as "Active IP" or a matched dummy "Vehicle") alongside either real light therapy (phototherapy) or a sham (fake) version of it. The four groups were: Active IP with real phototherapy (34 people), Active IP with sham phototherapy (37 people), vehicle with real phototherapy (31 people), and vehicle with sham phototherapy (12 people). The trial was measuring changes in facial vitiligo — a skin condition that causes...
-
NCT03270241 · results posted 9 January 2024
According to the results reported on ClinicalTrials.gov, this trial involved 10 participants, all of whom completed the study with no dropouts. The trial was looking at a type of light treatment called narrowband ultraviolet B (NB-UVB) phototherapy for vitiligo — a skin condition where patches of skin lose their colour. Specifically, the researchers were examining changes happening at a cellular and molecular level in both affected and unaffected skin, by measuring certain biological markers (proteins and signalling molecules in the skin) before and after the light treatment. The reported dat...
-
NCT04896385 · results posted 7 December 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 participants in total — 41 were assigned to ruxolitinib cream 1.5% (applied twice daily) and 19 to a vehicle cream (a cream with no active ingredient, used as a comparison). The trial ran in two stages: a 24-week double-blind period (where neither participants nor researchers knew who received which cream), followed by a 28-week extension period in which all participants used the active ruxolitinib cream. The trial was primarily measuring changes in a skin immune marker called CXCL10 — a protein linked to the infla...
-
NCT04547998 · results posted 21 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04547998) enrolled 50 adults with vitiligo — a skin condition that causes loss of skin colour in patches. Participants were split into two equal groups of 25. One group received ultraviolet B (UVB) light therapy alone (the control group), while the other received a combination treatment involving ablative laser resurfacing (a procedure that removes the outer skin layer), a cell-spray technique called RECELL, and UVB light therapy. All 50 participants completed the trial. The main thing the trial was measuring was how many...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04530344 · results posted 19 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04530344) enrolled 458 participants in total across four groups. It was an extension study for people with vitiligo — a skin condition that causes loss of skin colour — who had already taken part in a previous trial using ruxolitinib 1.5% cream or a dummy (vehicle) cream applied twice daily. The trial was measuring how long it took for facial skin improvements to fade, and how many participants maintained improvements in their facial vitiligo over the extension period. Skin improvement was tracked using a scoring system ca...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04818346 · results posted 5 July 2023
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called povorcitinib (tested at three different daily doses — 15 mg, 45 mg, and 75 mg) compared to a placebo (a dummy pill with no active ingredient) in people with vitiligo, a skin condition that causes loss of skin colour. A total of 171 people took part across the four groups at the start of the main 24-week phase. The trial's main question was whether povorcitinib changed the overall extent of vitiligo on the body, measured using a scoring system called the Total Vitiligo Area Scoring Index (T-VASI) — a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04052425 · results posted 21 September 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04052425) looked at a cream called ruxolitinib (1.5% strength, applied twice daily) compared with a "vehicle" cream — an identical-looking cream with no active ingredient — in people with vitiligo, a skin condition that causes patches of skin to lose their colour. The trial had two stages: a 24-week blinded period, where 221 people were randomly assigned to the ruxolitinib cream and 109 to the vehicle cream (neither the participants nor the investigators knew which cream each person was using); followed by a 28-week extens...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04057573 · results posted 21 September 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04057573) looked at a cream called ruxolitinib 1.5% in people with vitiligo — a skin condition where patches of skin lose their colour. The trial had two main phases. In the first 24-week phase, 229 people applied ruxolitinib cream twice daily and 115 people applied a "vehicle" cream (an identical-looking cream with no active ingredient) twice daily, without knowing which one they had received. Those who completed this phase then moved into a 28-week extension period where everyone used the ruxolitinib cream. The main thin...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03715829 · results posted 25 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03715829) tested different doses of an investigational medicine called PF-06651600 (also known as ritlecitinib) in people with non-segmental vitiligo — a skin condition where patches of skin lose their colour. The main dose-ranging phase enrolled 364 participants across five different dose groups and a placebo group (a dummy treatment with no active ingredient). A separate extension phase then followed, involving up to 293 additional participants across different treatment combinations. The trial's main goal was to measure...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04525157 · results posted 21 May 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT04525157) enrolled 18 participants who received a combination of two treatments: afamelanotide (an implant designed to stimulate skin pigmentation) and NB-UVB (a type of ultraviolet light therapy). The trial was measuring changes in vitiligo — a condition where patches of skin lose their colour — using a scoring system called the Vitiligo Area Scoring Index, or VASI. This score reflects how much of the body's skin surface is affected by vitiligo and how deeply the colour has been lost, with a lower score over time suggesti...
-
NCT03468855 · results posted 30 November 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03468855) enrolled 34 people who used a topical solution called ATI-50002 0.46% on their face. Of those 34 participants, 23 completed the study and 11 did not. The trial was measuring changes in facial depigmentation — that is, the amount of skin that had lost its colour — in a specific area of the face. Depigmentation was scored on a scale from 0 to 100, where 0 means no loss of skin colour and 100 means the entire area has lost colour. On this scale, lower scores represent a better outcome (less depigmentation). The rep...
-
NCT03933774 · results posted 12 August 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03933774) involved 25 people in total — 12 in one group and 13 in another. It was a side-by-side comparison, meaning each participant had tretinoin 0.05% cream applied to one side of the body and a placebo (inactive) cream applied to the other side at the same time. The trial was looking at changes in skin pigmentation (darkening of the skin) after 12 weeks. Of the 25 who started, 21 completed the study — 4 people did not finish (2 from each group). The reported data shows that skin lightness was measured using a special...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00622180 · results posted 5 November 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 participants in total — six in one group and seven in the other. Because this was a split-body study, each participant received two different light treatments at the same time, one on each side of their body. One group had the Daavlin light device used on their right side and the Excilite device on their left, while the other group had the opposite arrangement. The trial was measuring how much re-pigmentation (the return of skin colour) occurred in targeted skin patches, comparing two types of ultraviolet light the...
-
NCT02506101 · results posted 11 December 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT02506101) was designed to compare narrow-band ultraviolet B (UVB) light therapy against no treatment in people with vitiligo — a skin condition where patches of skin lose their colour. The trial planned to measure changes in the extent of skin colour loss using a scoring tool called the Vitiligo Area Scoring Index (VASI), as well as quality of life using two questionnaires, and some tissue-level changes in skin samples. Only 2 participants were enrolled in the light therapy group, and no participants were enrolled in the n...
-
NCT01992185 · results posted 10 March 2016
According to the results reported on ClinicalTrials.gov, this trial involved 15 people in total — 7 in the Photocil for Vitiligo group and 8 in the placebo group (who received a low-factor sunscreen, SPF 2). All 15 participants completed the trial with no drop-outs. The trial was measuring something called "percent repigmentation" — in other words, what percentage of skin colour returned to areas affected by vitiligo, a condition where patches of skin lose their pigment. The reported data shows that the Photocil group had an average of 48.5% repigmentation, while the placebo group had an aver...
-
NCT01517893 · results posted 12 March 2015
According to the results reported on ClinicalTrials.gov, this trial (NCT01517893) looked at whether high-dose simvastatin (a cholesterol-lowering medicine) could help reduce the skin patches caused by vitiligo — a condition where areas of skin lose their colour. A total of 15 people took part: 8 were assigned to receive the active treatment and 7 received a placebo (a dummy treatment with no active ingredient). Of those who started, 5 in the treatment group and all 7 in the placebo group completed the study; 3 people in the treatment group did not finish. The reported data shows that for the...
-
NCT01262547 · results posted 31 October 2014
According to the results reported on ClinicalTrials.gov, this trial (NCT01262547) enrolled 3 participants, all of whom had vitiligo — a skin condition where patches of skin lose their colour. All 3 participants completed the study. The trial was testing a skin procedure called dermabrasion-micrografting (where skin is lightly resurfaced and tiny skin grafts are transplanted) compared to dermabrasion alone and an untreated control area, measuring changes in skin repigmentation (the return of skin colour) over 24 weeks using a scoring tool called the Target VASI score. This score runs from 0 (no...
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, public investment in vitiligo research in the United States is at a moderate level, and encouragingly, that funding has been rising year on year. This upward trend suggests that the scientific community is paying increasing attention to vitiligo, which can be a positive sign for patients hoping to see new treatments emerge over time. Rising funding generally means mo...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.